Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $78.00.

LNTH has been the subject of several research analyst reports. Truist Financial boosted their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, December 18th. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Mizuho boosted their target price on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th.

Institutional Investors Weigh In On Lantheus

Several institutional investors and hedge funds have recently bought and sold shares of the business. Hantz Financial Services Inc. boosted its stake in Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 396 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in shares of Lantheus in the 2nd quarter worth approximately $26,000. First Horizon Corp acquired a new position in Lantheus during the 3rd quarter valued at approximately $26,000. Osterweis Capital Management Inc. bought a new position in Lantheus during the 2nd quarter worth $36,000. Finally, Farther Finance Advisors LLC grew its stake in Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 275 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 0.4%

Shares of NASDAQ:LNTH opened at $66.92 on Friday. The firm has a market cap of $4.44 billion, a PE ratio of 28.12 and a beta of -0.11. The company has a fifty day simple moving average of $64.87 and a 200 day simple moving average of $60.03. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.29.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, November 6th. The medical equipment provider reported $1.27 EPS for the quarter, meeting analysts’ consensus estimates of $1.27. The firm had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The firm’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.70 EPS. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, equities research analysts anticipate that Lantheus will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.